STAT3 and lung carcinoma: It has recently been reported that conventional therapies for lung cancer including chemotherapeutics and targeted therapies induce STAT3 activation 1,11,12, suggesting that STAT3 might be implicated in development of secondary drug resistance against conventional therapies.